share_log

Panbela Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Panbela Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Panbela Therapeutics | POS AM:修改注册声明表
美股SEC公告 ·  03/29 17:13
Moomoo AI 已提取核心信息
Panbela Therapeutics, Inc. filed a post-effective amendment to a Form S-1 registration statement with the Securities and Exchange Commission on March 29, 2024. The amendment pertains to the issuance of up to 8,750,000 shares of common stock underlying Class E and Class F common stock purchase warrants previously issued in a registered public offering. The shares are issuable upon exercise of the warrants at a price of $2.06 per share. The company's common stock is quoted on the OTC Pink Market under the symbol 'PBLA,' with the last reported sale price on March 26, 2024, being $0.64 per share. Panbela Therapeutics, a Delaware corporation with a primary standard industrial classification code number of 2834, is a clinical-stage biopharmaceutical company focused on developing treatments for patients with urgent unmet medical needs. The company's CEO is Jennifer K. Simpson, and its principal executive offices are located in Waconia, Minnesota. The proceeds from the exercise of the warrants are intended for the continued clinical development of Panbela's product candidates and for general corporate purposes.
Panbela Therapeutics, Inc. filed a post-effective amendment to a Form S-1 registration statement with the Securities and Exchange Commission on March 29, 2024. The amendment pertains to the issuance of up to 8,750,000 shares of common stock underlying Class E and Class F common stock purchase warrants previously issued in a registered public offering. The shares are issuable upon exercise of the warrants at a price of $2.06 per share. The company's common stock is quoted on the OTC Pink Market under the symbol 'PBLA,' with the last reported sale price on March 26, 2024, being $0.64 per share. Panbela Therapeutics, a Delaware corporation with a primary standard industrial classification code number of 2834, is a clinical-stage biopharmaceutical company focused on developing treatments for patients with urgent unmet medical needs. The company's CEO is Jennifer K. Simpson, and its principal executive offices are located in Waconia, Minnesota. The proceeds from the exercise of the warrants are intended for the continued clinical development of Panbela's product candidates and for general corporate purposes.
Panbela Therapeutics, Inc.于2024年3月29日向美国证券交易委员会提交了对S-1表格注册声明的生效后修正案。该修正案涉及发行最多8,750,000股标的E类和F类普通股购买权证,此前已在注册公开发行中发行。这些股票可在行使认股权证时以每股2.06美元的价格发行。该公司的普通股在场外粉红市场上市,股票代码为 “PBLA”,最后一次公布的销售价格为2024年3月26日,为每股0.64美元。Panbela Therapeutics是一家特拉华州公司,其主要标准行业分类代码为2834,是一家临床阶段的生物制药公司,专注于为医疗需求未得到满足的紧急患者开发治疗方法。该公司的首席执行官是詹妮弗·辛普森,其主要行政办公室位于明尼苏达州的瓦科尼亚。行使认股权证的收益将用于Panbela候选产品的持续临床开发和一般公司用途。
Panbela Therapeutics, Inc.于2024年3月29日向美国证券交易委员会提交了对S-1表格注册声明的生效后修正案。该修正案涉及发行最多8,750,000股标的E类和F类普通股购买权证,此前已在注册公开发行中发行。这些股票可在行使认股权证时以每股2.06美元的价格发行。该公司的普通股在场外粉红市场上市,股票代码为 “PBLA”,最后一次公布的销售价格为2024年3月26日,为每股0.64美元。Panbela Therapeutics是一家特拉华州公司,其主要标准行业分类代码为2834,是一家临床阶段的生物制药公司,专注于为医疗需求未得到满足的紧急患者开发治疗方法。该公司的首席执行官是詹妮弗·辛普森,其主要行政办公室位于明尼苏达州的瓦科尼亚。行使认股权证的收益将用于Panbela候选产品的持续临床开发和一般公司用途。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息